Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploring delta-receptor function using the selective opioid antagonist naltrindole.

H C Jackson1, T L Ripley, D J Nutt

  • 1Reckitt and Colman Psychopharmacology Unit, School of Medical Sciences, Bristol, England.

Neuropharmacology
|December 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human brain changes after first psilocybin use.

Nature communications·2026
Same author

Serotonergic psychedelics for depression: A comprehensive overview.

International review of neurobiology·2025
Same author

Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study.

Archives of suicide research : official journal of the International Academy for Suicide Research·2024
Same author

Psilocybin and Other Classic Psychedelics in Depression.

Current topics in behavioral neurosciences·2023
Same author

Canalization and plasticity in psychopathology.

Neuropharmacology·2022
Same author

Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21.

Psychopharmacology·2021
Same journal

Thyrotropin-releasing hormone and dopaminergic systems interact in the ventral tegmental area to regulate food intake in rats.

Neuropharmacology·2026
Same journal

TRPC5 as a modulator of TRPV1 signalling in pathological pain states.

Neuropharmacology·2026
Same journal

Loss of mGlu<sub>5</sub> receptors from PV inhibitory neurons attenuates sex differences in ethanol and sucrose seeking.

Neuropharmacology·2026
Same journal

PM289, a synthetic CB2 in vitro receptor agonist, modulates morphine-induced antinociceptive effect and withdrawal syndrome in an animal model of osteoarthritic pain.

Neuropharmacology·2026
Same journal

Purinergic-cytokine signaling as a regulatory axis in neuroimmune development.

Neuropharmacology·2026
Same journal

Acupuncture improves depressive symptoms and prefrontal cortical function in mild to moderate depressive disorder: A randomized sham-controlled trial and fNIRS study.

Neuropharmacology·2026
See all related articles

A new non-peptide delta-receptor antagonist, naltrindole, effectively reduced pain responses in a stress model. This offers a promising, potentially safer alternative to existing peptide-based delta-receptor probes.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Receptor Binding Assays

Background:

  • Peptide enkephalin analogues were the primary pharmacological tools for studying delta-receptors.
  • These peptide analogues present limitations such as high cost, partial agonism, and neurotoxicity.

Purpose of the Study:

  • To investigate the intrinsic actions of the novel non-peptide delta-receptor antagonist, naltrindole.
  • To evaluate naltrindole's efficacy as a potential alternative to existing delta-receptor antagonists.

Main Methods:

  • Exploration of naltrindole's intrinsic pharmacological actions.
  • Assessment of naltrindole's effect on swim stress-induced antinociception in a rodent model.

Main Results:

  • Naltrindole demonstrated efficacy in attenuating antinociception induced by swim stress.

Related Experiment Videos

  • This indicates naltrindole's potential as a functional antagonist for endogenous delta-receptor activation.

    • Conclusions:

    • Naltrindole represents a viable non-peptide antagonist for delta-receptors.
    • It may serve as a valuable and potentially safer alternative to current peptide-based pharmacological probes.